U.S. Markets closed

Poseida Therapeutics, Inc. (PSTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
11.46+0.36 (+3.24%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close11.10
Open11.01
Bid11.16 x 1100
Ask14.00 x 900
Day's Range10.77 - 11.59
52 Week Range7.63 - 17.62
Volume47,239
Avg. Volume186,178
Market Cap708.457M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Poseida Therapeutics Reports Operational Update and Financial Results for Third Quarter 2020
    PR Newswire

    Poseida Therapeutics Reports Operational Update and Financial Results for Third Quarter 2020

    Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced an operational update and financial results for the quarter ended September 30, 2020.

  • Poseida Therapeutics Announces Clinical Hold Lifted on Phase I Autologous CAR-T Study in Prostate Cancer
    PR Newswire

    Poseida Therapeutics Announces Clinical Hold Lifted on Phase I Autologous CAR-T Study in Prostate Cancer

    Poseida Therapeutics, Inc., (Nasdaq: PSTX), a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure, today announced the U.S. Food and Drug Administration (FDA) has lifted a clinical hold on the Company's Phase 1 study of P-PSMA-101 in metastatic castration-resistant prostate cancer (mCRPC) and plans to resume the trial immediately. P-PSMA-101 is the company's first solid tumor autologous CAR-T therapeutic candidate.

  • Poseida Therapeutics and TScan Therapeutics Announce Research Collaboration and License Agreement to Explore Developing Allogeneic T Cell Receptor Therapies for the Treatment of COVID-19
    PR Newswire

    Poseida Therapeutics and TScan Therapeutics Announce Research Collaboration and License Agreement to Explore Developing Allogeneic T Cell Receptor Therapies for the Treatment of COVID-19

    Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, and TScan Therapeutics, Inc., a biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies in oncology, today announced a research collaboration and license agreement to explore developing TCR-T cell therapies for the treatment of COVID-19. Poseida's allogeneic T cell platform will be used in combination with TScan's discovered immunodominant epitopes and TCR sequences for the development and commercialization of allogeneic TCR-T cell therapies.